XEN1101 (Kv7 opener)
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
PRE
P1
P2
P3
Edit
Updated: 05/17/2019
Pipeline Type
New Drugs in Development
Phase Of Development
Phase 1
Sponsors and Collaborators
Xenon Pharma
Mechanism of Action
Ion Channel
Mechanism Description
Potasium channel opener
Populations Tested In
drug resistant focal epilepsy, rare epilesies with K mutations
Other Resources
Special FDA Designation
Nonprofit or Government Support
N/A
Nonprofit or Government Support Description
N/A
Previous Presentations
Presented at meetings (latest date) (Pipeline, AEDD; AES, Eilat, etc)
N/A
Location of Clinical Trials
N/A
Clinical Trial link